**Specifications Table**TableSubject areaClinical chemistry, hematologyMore specific subject areaCoagulation analysis, prothrombin time analysis, INRType of dataFigures (scatter plots, histograms), tablesHow data was acquiredCoaguChek XS (Roche Diagnostics), Star Evolution (Stago), BCS XP (Siemens Medical Solutions) coagulation analyzersData formatRaw and analyzedExperimental factorsDescribed in the methods sectionExperimental featuresDescribed in the methods sectionData source locationUTMB (Galveston, TX), ARUP (Salt Lake City, UT), CPL (Austin, TX)Data accessibilityRaw sample data in [Table 1](#t0005){ref-type="table"} and ECAA standards data Ref. [@bib1]

**Value of the data**•The data indicate that although agreement between central lab methods was improved by the PT/INR line correction, the INR results continued to exhibit statistically significant site dependence.•The raw data here may provide insight pertinent to INR standardization efforts.•Although the PT/INR line correction method is designed to minimize INR variation due to differences in instrumentation, thromboplastin, and local ISI correction strategy, the data indicate a need for method innovation. Additionally, a method [@bib5] which allows for standardization of INR results obtained from disparate sample types (e.g. whole blood and plasma) would be beneficial.

1. Data {#s0005}
=======

[Fig. 1](#f0005){ref-type="fig"} shows the European Concerted Action on Anticoagulation (ECAA) Poller calibrant-generated PT/INR lines for the Stago Star Evolution instruments at the University of Texas Medical Branch (UTMB, [Fig. 1](#f0005){ref-type="fig"}A), the Associated Regional and University Pathologists, Inc. (ARUP, [Fig. 1](#f0005){ref-type="fig"}B), and the Siemens BCS XP at Clinical Pathology Laboratories, Inc. (CPL, [Fig. 1](#f0005){ref-type="fig"}C). The calibrant data provide a linear fit to the model for all methods, as evidenced by their coefficients of determination (*R*^2^\>0.998). The generation of the calibrations plots and PT/INR line method is described briefly in the methods section and detailed more fully by Poller et al. [@bib2], [@bib3], [@bib4].Fig. 1PT/INR calibration line and regression analysis generated from testing of ECAA Poller calibrants by (A) UTMB Stago Star Evolution, (B) ARUP Stago Star Evolution, and (C) CPL Siemens BCS XP.Fig. 1

The PT/INR line fit was employed to correct central lab INR results for 100 warfarin therapy and 20 control samples examined as part of a CoaguChek XS point-of-care device study, as detailed in [Table 1](#t0005){ref-type="table"} [@bib1]. [Fig. 2](#f0010){ref-type="fig"}A shows the frequency distribution of the uncorrected INR values for the central lab and CoaguChek XS coagulometers. Visual inspection of the histograms in [Fig. 2](#f0010){ref-type="fig"}A show that the recombinant human thromboplastin based methods (Coaguchek XS and BCS) have similar INR frequency distributions. Additionally, the rabbit brain thromboplastin based methods (UTMB and ARUP Stago) INR frequency distributions exhibit a comparable pattern. In [Fig. 2](#f0010){ref-type="fig"}B the PT/INR line corrected INR results are shown for all central laboratory methods alongside the uncorrected CoaguChek XS data (the POCT device is only approved for analysis of whole blood samples thus could not be calibrated using the plasma-based ECAA Poller standards[@bib5]). Visual inspection of [Fig. 2](#f0010){ref-type="fig"}B reveals no obvious improvement in the net agreement between methods, however, Pearson\'s chi-squared testing of the frequency distribution data shown in [Table 2](#t0010){ref-type="table"} provided *χ*^2^=33.36 with *p*=0.00005 (before PT/INR line correction) and *χ*^2^=25.56 with *p*=0.012 (after PT/INR line correction). The chi-squared test results showed that although the PT/INR line correction method failed to provide inter-method agreement at the *p*=0.05 threshold, improved agreement was observed.Fig. 2Sample population INR distribution (A) before (raw data) and (B) after PT/INR line correction (see Ref. [@bib2]) using ECAA Poller standards.Fig. 2Table 1Raw and PT/INR line corrected sample data.SampleRoche XSUTMB StagoARUP StagoCPL BCS XPSecINRSecINRPT/INR correctedSecINRPT/INR correctedSecINRPT/INR corrected3N11.401.0012.600.900.8312.000.900.879.900.900.8010N11.100.9012.600.900.8312.601.000.9210.201.000.8319N11.601.0012.500.900.8213.001.000.9611.301.100.9220N10.800.9012.500.900.8212.900.900.959.900.900.80IN11.701.0013.001.000.8712.801.000.9411.101.100.902N11.300.9013.101.000.8812.801.000.9410.000.900.814N12.201.0013.301.000.9013.501.101.0110.601.000.865N12.701.1013.701.000.9313.601.101.0211.201.100.916N11.001.0013.401.000.9013.101.000.9710.301.000.837N11.501.0013.301.000.9012.200.900.8910.601.000.868N11.400.9013.101.000.8813.101.000.9710.301.000.839N11.401.0012.901.000.8612.401.000.91NANANA11N10.800.9012.901.000.8613.201.000.989.900.900.8012N11.300.9013.301.000.9013.001.000.9610.401.000.8413N10.400.9013.301.000.9012.901.000.9510.201.000.8314N10.600.9013.501.000.9113.301.000.9910.801.000.8715N11.000.9013.301.000.9013.201.000.9810.801.000.8716N11.300.9013.001.000.8712.901.000.9511.101.100.9017N11.701.0013.401.000.9012.901.000.9510.701.000.8718N11.300.9013.001.000.8713.001.000.9610.601.000.8610A15.601.3014.401.100.9914.201.101.0711.401.100.9239A14.201.2015.601.201.1115.101.201.1611.801.100.961A16.601.4016.301.301.1716.701.401.3113.901.401.1317A16.201.4017.301.401.2716.501.401.2914.501.401.1844A14.701.2016.901.401.2316.101.301.2513.401.301.0926A21.801.8019.101.601.4519.501.701.5919.902.001.6234A20.401.7019.501.601.4919.701.701.6117.201.701.4036A22.701.9019.601.601.5019.301.701.5719.602.001.596A21.501.8020.401.701.5819.901.801.6318.201.801.4812A24.102.0020.101.701.5519.201.701.5616.901.701.3720A26.002.2020.501.701.5920.301.801.6718.901.901.5442A23.802.0020.001.701.5420.301.801.6718.801.901.5314A22.301.9021.301.801.6720.601.801.7119.001.901.5532A23.301.9021.201.801.6621.001.901.7519.902.001.6247A23.402.0020.801.801.6221.001.901.7522.902.301.8751A25.202.1020.901.801.6320.301.801.6720.602.101.6877A23.802.0021.301.801.6721.602.001.8120.502.101.677A27.002.2021.601.901.7021.802.001.8323.602.401.9224A28.302.4022.301.901.7725.002.402.1724.002.401.9627A24.802.1021.801.901.7221.401.901.7919.301.901.5735A25.202.1022.001.901.7421.702.001.8219.401.901.5849A26.002.2021.801.901.7221.501.901.8021.502.201.7518A25.102.1022.902.001.8421.802.001.8320.002.001.6325A26.002.2023.002.001.8522.902.101.9519.602.001.5973A25.602.1022.702.001.8222.102.001.8622.302.201.8230A25.602.1023.702.101.9225.502.202.2321.502.101.7572A25.402.1023.602.101.9123.002.101.9622.002.201.7975A28.002.3023.902.101.9423.202.101.9822.402.201.8297A28.202.3024.102.101.9723.802.202.0423.002.301.875A28.302.4024.402.202.0024.002.202.0623.602.401.929A27.802.3024.602.202.0224.302.302.1023.602.401.9241A34.102.8024.802.202.0425.502.402.2327.502.702.2454A30.402.5024.602.202.0223.702.202.0323.402.301.9180A31.302.6024.602.202.0225.402.402.2125.802.602.1091A35.302.9025.002.202.0624.602.302.1327.702.802.2695A31.402.6025.002.202.0624.902.302.1624.302.401.9813A31.302.6025.102.302.0724.502.302.1223.002.301.8722A41.103.4025.202.302.0926.402.502.3223.902.401.9545A30.402.5025.602.302.1325.402.402.2127.802.802.2750A37.803.1025.402.302.1125.402.402.2131.003.102.5382A34.502.9025.102.302.0725.002.402.1726.602.702.1784A34.302.9025.102.302.0725.802.402.2628.402.802.3290A38.803.2025.502.302.1225.702.402.2529.703.002.4294A32.102.7025.902.302.1625.802.402.2626.502.602.162A33.402.8026.602.402.2427.202.602.4130.303.002.4719A32.902.7026.202.402.2025.802.402.2625.202.502.0523A30.902.6026.602.402.2426.702.602.3626.402.602.1533A30.002.5026.102.402.1825.402.402.2124.202.401.9737A31.602.6026.202.402.2025.802.402.2627.602.802.2546A34.202.8026.202.402.2025.702.402.2525.602.602.0952A33.402.8026.102.402.1826.002.502.2829.502.902.4155A33.602.8026.402.402.2226.002.502.2828.802.902.3587A36.403.0026.702.402.2527.402.602.4327.902.802.2898A33.802.8026.502.402.2326.702.602.3630.203.002.4715A37.403.1027.602.502.3527.002.602.3929.703.002.4253A39.103.3027.502.502.3428.002.702.5032.203.202.6364A39.503.3027.202.502.3126.902.602.3829.102.902.3848A32.902.7028.202.602.4227.802.702.4828.602.802.3358A45.403.8027.702.602.3629.502.902.6737.403.703.0666A37.603.1028.302.602.4329.202.902.6434.103.402.7979A41.203.4028.402.602.4428.202.802.5231.703.102.5996A37.203.1028.202.602.4228.302.802.5331.003.102.5399A43.203.6027.702.602.3628.102.702.5134.803.402.8411A37.903.2029.102.702.5228.402.802.5532.303.202.6421A29.902.5028.602.702.4728.702.802.5830.103.002.4631A35.403.0028.602.702.4728.702.802.5828.902.902.3643A41.103.4028.802.702.4928.402.802.5536.803.603.0163A43.003.6029.302.702.5532.103.202.9742.004.103.4483A38.203.2028.602.702.4728.902.802.6032.003.202.6186A32.102.7042.902.704.2127.902.702.4928.402.802.3293A40.403.4028.702.702.4829.602.902.6835.003.402.863A42.703.6030.102.802.6430.003.002.7335.003.502.8638A36.303.0030.002.802.6329.602.902.6830.203.002.4762A44.403.7029.902.802.6128.802.802.5932.503.202.6681A44.603.7029.802.802.6030.603.002.7934.603.402.8392A42.503.5029.402.802.5629.602.902.6834.103.402.794A43.203.6030.202.902.6530.703.102.8135.103.502.8771A53.204.4030.202.902.6530.803.102.8242.304.103.4674A48.004.0030.802.902.7230.903.102.8338.303.803.1388A38.603.2030.502.902.6830.003.002.7332.003.202.6159A49.404.1031.403.002.7932.103.202.9737.403.703.0628A36.703.1032.003.102.8631.603.202.9129.702.902.4229A44.203.7032.103.102.8731.903.202.9437.703.703.0869A44.003.7031.903.102.8531.503.202.9042.204.103.4516A61.005.1033.203.203.0033.703.403.1545.004.403.6967A50.004.2034.103.303.1132.503.303.0137.403.703.0685A51.804.3033.803.303.0734.803.603.2848.004.603.93100A53.304.4034.603.403.1736.903.903.5353.005.104.358A57.404.8035.703.503.3134.403.503.2342.004.103.4440A55.604.6035.503.503.2835.703.703.3950.004.804.1061A53.004.4035.603.503.2936.303.803.4641.904.103.4368A56.004.7035.703.503.3135.003.603.3047.104.603.8670A45.703.8035.003.503.2234.003.503.1943.004.203.5276A59.405.0035.603.503.2936.903.903.5350.204.804.1256A65.405.5037.103.703.4837.704.003.6245.904.403.7665A55.604.6038.303.903.6337.604.003.6145.904.503.7678A61.205.1038.103.903.6039.404.203.8357.105.404.6957A65.405.4039.104.003.7337.904.003.6548.904.704.0160A59.405.0039.804.103.8240.104.303.9149.804.804.0889A64.205.3046.004.904.6244.004.904.4061.405.805.04Table 2Frequency distribution of INR values before and after PT/INR line correction.Table 2**Before PT/INR correction**TotalINR\<22≤INR\<33≤INR\<44≤INR\<5INR≥5CoaguChek XS314229117120UTMB Stago42581730120ARUP Stago38552160120BCS324227153119Total143197943510479**After PT/INR line correction**CoaguChek XS (uncorrected)314229117120UTMB Stago43541751120ARUP Stago40482291120BCS393724811119Total153181923320479

One-way repeated measures ANOVA was performed to investigate correspondence between methods both before and after PT/INR line correction. Because the raw and PT/INR line corrected data failed the Mauchly\'s Test for Sphericity (*p*=6.17e-59 before correction and *p*=1.30e-37 after correction), a Greenhouse-Geisser correction was applied to all ANOVA models. The p-values for one-way repeated measures ANOVA of the raw and corrected INR data for all methods were 3.52e-24 and 8.91e-14, respectively, indicating improved but statistically significant inter-method variation. In order to identify the source of the variation, paired t-test were performed both before and after PT/INR line correction, as shown in [Table 3](#t0015){ref-type="table"}. While the p-values show that inter-method agreement improved for all methods following PT/INR correction, only the human thromboplastin based methods (BCS and uncorrected CoaguChek XS) showed agreement exceeding the *p*=0.05 threshold.Table 3Paired t-test analysis of INR results before and after PT/INR line correction.Table 3**Before PT/INR line correction**ARUP StagoBCSUTMB StagoBCS\<2e-16----UTMB Stago\<2e-16\<2e-16--CoaguChek XS1e-150.08\<2e-16  **After PT/INR line correction**BCS2.6e-07----UTMB Stago9.5e-091.7e-09--CoaguChek XS9.2e-120.478.0e-14

2. Experimental design, materials and methods {#s0010}
=============================================

The study protocol was approved for verbal informed assent by the Institutional Review Board of the University of Texas Medical Branch (UTMB) and Roche Diagnostics USA (Indianapolis, IN). Warfarin therapy patients were recruited from March to May 2015 during routine visits to monitor their PT/INR at UTMB\'s anti-coagulation clinic and all POCT measurements were performed on the CoaguChek XS by a single trained nurse. The warfarin patients seen in the anti-coagulation clinic were routinely monitored and Coumadin dosage changed using the CoaguChek XS results. POCT PT/INR results \>5.0 were sent to the main laboratory for confirmation. The POCT PT/INR was determined prior to asking the patient if they would be willing to be included in the study. If willing to participate the subject was taken to phlebotomy to have a venous blood sample drawn in 3.2% citrate, where the first 1 ml of venous blood was discarded. The sample was then transferred to the laboratory where it was centrifuged at \>3000x*g* for 10 min to prepare platelet poor plasma. Within 4 h of sample collection an aliquot of the platelet poor plasma was analyzed for PT/INR in the main UTMB Pathology laboratory on the Stago Star Evolution (Diagnostic Stago Inc., Mount Olive, NJ). Additional aliquots were prepared and frozen for later analysis of PT INR on the Stago Star Evolution (Stago, Parsippany, NJ) located at ARUP Labs (Salt Lake, UT) and the Siemens BCS (Siemens Medical Solutions USA, Inc., Malvern, PA) located at CPL (Austin, TX). The Stago Star Evolution used rabbit brain thromboplastin (UTMB ISI=1.25; ARUP ISI=1.28) and the CoaguChek XS and Siemens BCS used recombinant human thromboplastin (ISI=1.01 and 1.02, respectively).

The 20 normal (non-warfarin) samples and 100 warfarin treatment samples were included in this investigation. All warfarin therapy samples were obtained from patients who have been on stabilized warfarin therapy for at least one month to allow both short half-life (Factor VII) and long half-life vitamin K-dependent clotting factors to attain therapeutic equilibria. Patients included in this study are expected, based on their medical history, to be negative for anti-phospholipid antibodies, have hematocrit values in the 25--55% range, and have taken no additional anticlotting medication such as aspirin.

2.1. PT INR measurement {#s0015}
-----------------------

PT INR measurements were performed using the POCT CoaguChek XS system (UTMB anticoagulation clinic), core laboratory Star Evolution (at UTMB and ARUP), and BCS XP (at CPL). INR measurements were obtained for all 120 samples, using all methods except for one BCS sample. The CoaguChek XS system detects coagulation in a drop of whole blood while the central lab methods employ citrated plasma (as described above). The CoaguChek XS and the BCS XP use a human recombinant thromboplastin while the Star Evolution uses rabbit brain thromboplastin (STA Neoplastin). A single CoaguChek XS device and only one lot of test strips were used for this study.

2.2. Calibrant standards and controls {#s0020}
-------------------------------------

Poller calibrants (European Concerted Action on Anticoagulation or ECAA PT/INR plasma set, batch 1591-6) were purchased from Hart Biologicals Ltd. (Hartlepool, England). The frozen standards and controls were stored and prepared according to vendor specifications prior to analysis in duplicate on the three central laboratory analyzers.

2.3. PT/INR line correction {#s0025}
---------------------------

INR data from the Stago and BCS XP were corrected using the regression equation generated from ln(PT observed) vs ln(INR certified) calibration plots obtained from central lab analysis of the ECAA Poller calibrant [@bib2], [@bib3], [@bib4]. The certified Poller INR values were obtained from the manufacturer and the values for the specified thromboplastins were employed (See Table 2A, Ref. [@bib1]). Linear regression analysis was performed to generate the PT/INR regression line (*y*=*mx*+*b*), where *x*=ln(INR certified), *y*=ln(PT observed), *m*=slope, *b*=intercept, and *y*=*mx*+*b*. The PT/INR line corrected sample INR values (shown in [Table 1](#t0005){ref-type="table"}) were generated using the rearranged equation *x*=(−*b*/*m*)+(1/*m*)*y* by inputting *y*=ln(sample PT) and raising *x*=ln(INR corrected) to the natural exponent (e^ln(INR\ corrected)^=INR corrected).

2.4. Statistical Analysis {#s0020a}
-------------------------

Pearson\'s chi-square testing, paired t-tests, and one-way repeated measures ANOVA were performed using R 3.4.
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